 |  |  |  |  |
THIS WEBSITE TALKS ABOUT THE SIDE EFFECTS AND THE POTENTIAL HEALTH BENEFITS OF HERBS, SUPPLEMENTS,
PHYTONUTRIENTS AND DRUG PRODUCTS. THIS WEBSITE ALSO TALKS ABOUT SOME POPULAR HEALTH ISSUES AND DISEASES.
ARTICLES IN THIS WEB SITE IS FOR YOUR REFERENCE ONLY. IF YOU HAVE ANY QUESTION, YOU SHOULD CONSULT WITH YOUR
DOCTOR IMMEDIATELY. ALL RIGHTS RESERVED 2008. DO NOT COPY NOR TRANSFER ARTICLES TO OTHER WEBSITES NOR OTHER
FORMS OF PUBLICATIONS. Privacy Policy. ARTICLE INDEX
PHYTONUTRIENTS AND DRUG PRODUCTS. THIS WEBSITE ALSO TALKS ABOUT SOME POPULAR HEALTH ISSUES AND DISEASES.
ARTICLES IN THIS WEB SITE IS FOR YOUR REFERENCE ONLY. IF YOU HAVE ANY QUESTION, YOU SHOULD CONSULT WITH YOUR
DOCTOR IMMEDIATELY. ALL RIGHTS RESERVED 2008. DO NOT COPY NOR TRANSFER ARTICLES TO OTHER WEBSITES NOR OTHER
FORMS OF PUBLICATIONS. Privacy Policy. ARTICLE INDEX
 | |  |
Brlinta side effects and its use
Brilinta (ticagrelor, AZD6140) works by stopping the blood's ability to clot. Brilinta
(ticagrelor), the first reversibly binding oral P2Y(12) receptor antagonist, blocks adenosine
diphosphate (ADP)-induced platelet aggregation via a mode of action distinct from that of
thienopyridine antiplatelet agents. The latter must be metabolically activated and binds
irreversibly to P2Y(12) for the life of the platelet, precluding restoration of hemostatic
function without the generation of new platelets. [4] Ticagrelor is not a prodrug and exhibits
a more rapid onset of action than the thienopyridine prodrugs. In clinical trials conducted to
date, ticagrelor was a potent inhibitor of ADP-induced platelet aggregation and
demonstrated effects that were comparable to clopidogrel. [3]
The Plato study, financed by AstraZeneca and presented at the European Society of
Cardiology's annual meeting in Barcelona, found that Brilinta did not increase the overall
risk of dangerous bleeding compared to Plavix. There was an increase in minor bleeding
and bleeding away from the heart. [2] These showed that patients with acute coronary
syndrome (ACS) who took Brilinta were 16 percent less likely than those on Plavix to die
from cardiovascular causes or suffer a heart attack or stroke. [1]
Plavix is sold by Sanofi- and Bristol-Myers Squibb's. It already faces one rival in Eli Lilly
and Daiichi Sankyo's recently launch Effient, which has also outperformed Plavix in tests.
But Effient, also known as prasugrel, is hampered by a strict warning on bleeding risks. [1]
Following the Phase Three trial, which included 18,624 patients, AstraZeneca will seek to
file for regulatory approval of the drug for Europe and the US in the fourth quarter. [2]
What are the Common Side Effects of Brilinta (ticagrelor)?
Brilinta may have different side effects. In a phase II, short-term trial, the bleeding profile of
participants treated with ticagrelor was similar to that obtained with clopidogrel; however,
an increased incidence of dyspnea was observed - an effect that has not been reported
with the thienopyridines. [3]
Reference
[1] Astra drug beats Plavix without major bleed risk Reuters Sun Aug 30, 2009 2:00am [2]
AstraZeneca's heart attack drug offers £5.5bn boost telegraph.co.uk 30 Aug 2009 [3]
Doggrell SA. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and
treatment of arterial thrombosis and acute coronary syndromes. IDrugs. 2009
May;12(5):309-17. [4] van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA.
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and
antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
Thromob Res. 2009 Aug 17
(ticagrelor), the first reversibly binding oral P2Y(12) receptor antagonist, blocks adenosine
diphosphate (ADP)-induced platelet aggregation via a mode of action distinct from that of
thienopyridine antiplatelet agents. The latter must be metabolically activated and binds
irreversibly to P2Y(12) for the life of the platelet, precluding restoration of hemostatic
function without the generation of new platelets. [4] Ticagrelor is not a prodrug and exhibits
a more rapid onset of action than the thienopyridine prodrugs. In clinical trials conducted to
date, ticagrelor was a potent inhibitor of ADP-induced platelet aggregation and
demonstrated effects that were comparable to clopidogrel. [3]
The Plato study, financed by AstraZeneca and presented at the European Society of
Cardiology's annual meeting in Barcelona, found that Brilinta did not increase the overall
risk of dangerous bleeding compared to Plavix. There was an increase in minor bleeding
and bleeding away from the heart. [2] These showed that patients with acute coronary
syndrome (ACS) who took Brilinta were 16 percent less likely than those on Plavix to die
from cardiovascular causes or suffer a heart attack or stroke. [1]
Plavix is sold by Sanofi- and Bristol-Myers Squibb's. It already faces one rival in Eli Lilly
and Daiichi Sankyo's recently launch Effient, which has also outperformed Plavix in tests.
But Effient, also known as prasugrel, is hampered by a strict warning on bleeding risks. [1]
Following the Phase Three trial, which included 18,624 patients, AstraZeneca will seek to
file for regulatory approval of the drug for Europe and the US in the fourth quarter. [2]
What are the Common Side Effects of Brilinta (ticagrelor)?
Brilinta may have different side effects. In a phase II, short-term trial, the bleeding profile of
participants treated with ticagrelor was similar to that obtained with clopidogrel; however,
an increased incidence of dyspnea was observed - an effect that has not been reported
with the thienopyridines. [3]
Reference
[1] Astra drug beats Plavix without major bleed risk Reuters Sun Aug 30, 2009 2:00am [2]
AstraZeneca's heart attack drug offers £5.5bn boost telegraph.co.uk 30 Aug 2009 [3]
Doggrell SA. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and
treatment of arterial thrombosis and acute coronary syndromes. IDrugs. 2009
May;12(5):309-17. [4] van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA.
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and
antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
Thromob Res. 2009 Aug 17